Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

92
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
92
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

871
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
871
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.9K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.9K
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

784
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
784
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

228
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
228
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

150
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
150

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study.

The lancet. Diabetes & endocrinology·2017
Same author

The association of lipoprotein(a) with incident heart failure hospitalization: Atherosclerosis Risk in Communities study.

Atherosclerosis·2017
Same author

Serum vitamin D and change in lipid levels over 5 y: The Atherosclerosis Risk in Communities study.

Nutrition (Burbank, Los Angeles County, Calif.)·2017
Same author

A simplified pathway to proprotein convertase subtilisin/kexin type 9 inhibitor prior authorization approval: A lipid clinic experience.

Journal of clinical lipidology·2017
Same author

The Upregulation of Integrin α<sub>D</sub>β<sub>2</sub> (CD11d/CD18) on Inflammatory Macrophages Promotes Macrophage Retention in Vascular Lesions and Development of Atherosclerosis.

Journal of immunology (Baltimore, Md. : 1950)·2017
Same author

Dyslipidaemia: PCSK9 inhibitors and foamy monocytes in familial hypercholesterolaemia.

Nature reviews. Cardiology·2017
Same journal

The Heart-Brain Connection.

Cardiology clinics·2026
Same journal

Overcoming Psychological Barriers to Treatment Adherence: The Case of Antihypertensive Medication.

Cardiology clinics·2026
Same journal

Cardio-oncology Rehabilitation and Mental Health: Current Evidence and Future Perspectives.

Cardiology clinics·2026
Same journal

Cardiac Rehabilitation and Mental Health.

Cardiology clinics·2026
Same journal

Best-Practice Mental Health Interventions Following Acute Cardiovascular Events.

Cardiology clinics·2026
Same journal

Positive Psychology Interventions and Cardiovascular Health: Frequency and Duration to Sustain Cardiovascular Benefits.

Cardiology clinics·2026
See all related articles

Related Experiment Video

Updated: Apr 13, 2026

Assessing Whole-Body Lipid-Handling Capacity in Mice
07:57

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

4.9K

Genetic testing in hyperlipidemia.

Ozlem Bilen1, Yashashwi Pokharel2, Christie M Ballantyne3

  • 1Department of Medicine, Baylor College of Medicine, 3131 Fannin Street, Houston, TX 77030, USA.

Cardiology Clinics
|May 6, 2015
PubMed
Summary
This summary is machine-generated.

Hereditary lipid disorders like familial hypercholesterolemia are often missed. Genetic testing offers accurate diagnosis and improved family screening for preventing cardiovascular disease.

Keywords:
DyslipidemiaFamilial hypercholesterolemiaGenetic testingHereditary lipid disorder

More Related Videos

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
10:56

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

Published on: September 15, 2018

8.6K
Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.9K

Related Experiment Videos

Last Updated: Apr 13, 2026

Assessing Whole-Body Lipid-Handling Capacity in Mice
07:57

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

4.9K
A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
10:56

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

Published on: September 15, 2018

8.6K
Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.9K

Area of Science:

  • Cardiovascular Medicine
  • Genetics
  • Clinical Diagnostics

Background:

  • Hereditary dyslipidemias frequently lead to preventable premature cardiovascular diseases.
  • Current clinical diagnostic criteria for lipid disorders lack sensitivity.
  • Underdiagnosis and undertreatment of these conditions are significant clinical challenges.

Purpose of the Study:

  • To review the clinical utility of genetic testing for diagnosing hereditary lipid disorders.
  • To highlight the role of genetic testing in familial hypercholesterolemia management.
  • To explore genetic testing's potential in risk stratification and therapeutic decisions.

Main Methods:

  • Literature review focusing on genetic testing applications in dyslipidemias.
  • Analysis of diagnostic accuracy and sensitivity of genetic versus clinical criteria.
  • Examination of genetic testing's impact on cascade screening and patient management.

Main Results:

  • Genetic testing provides higher diagnostic accuracy for hereditary dyslipidemias compared to clinical criteria alone.
  • Genetic confirmation facilitates effective cascade screening, identifying affected relatives.
  • Genetic information may aid in personalized risk assessment and treatment selection.

Conclusions:

  • Genetic testing is a valuable tool for accurate diagnosis of hereditary dyslipidemias.
  • Implementing genetic testing can enhance cascade screening and family-based interventions.
  • Genetic insights hold promise for refining risk stratification and guiding therapy in lipid disorders.